Skip to content
Evigrade
CriticalClass III antiarrhythmic, selective IKr blocker×Antianginal – late sodium current inhibitor

Updated · Methodology

Mechanism

Ranolazine blocks the IKr potassium current and prolongs the heart-rate-corrected QT interval (QTc) in a concentration-dependent way (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Dofetilide is a class III antiarrhythmic that blocks the same IKr current, and the QT interval increases linearly with its dose and plasma concentration (dofetilide label, US Food and Drug Administration, FDA). The kidneys eliminate dofetilide, partly through cationic secretion. According to its US label, metformin also undergoes active secretion by this route (FDA). Ranolazine inhibits the organic cation transporter OCT2 in vitro and raises metformin exposure 1.4–1.8-fold (ranolazine SmPC, EMA, and FDA label). Ranolazine is also a weak inhibitor of CYP3A4 (EMA), which metabolises dofetilide to a small extent (FDA). The documents give no figures on how ranolazine changes dofetilide levels.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Dofetilide can cause serious ventricular arrhythmias, mainly torsade de pointes. In studies of people with supraventricular arrhythmias, torsade de pointes occurred in 0.8%, more often at higher doses (dofetilide label, US Food and Drug Administration, FDA). Reduced creatinine clearance and some drug interactions raise dofetilide levels, and low potassium and magnesium increase the risk of torsade de pointes (dofetilide FDA label). Warning signs of a possible arrhythmia are feeling faint or lightheaded and an irregular or fast heartbeat (ranolazine FDA label).

Management

The combination is contraindicated. The European ranolazine summary of product characteristics (SmPC) contraindicates ranolazine with class Ia and class III antiarrhythmics other than amiodarone and names dofetilide (ranolazine SmPC, European Medicines Agency, EMA). Dofetilide is not authorised in Spain. Its US label says that use with other QT-prolonging drugs has not been studied and is not recommended. The label advises caution with CYP3A4 inhibitors and contraindicates inhibitors of renal cation secretion (dofetilide label, US Food and Drug Administration, FDA). The US ranolazine label is milder than the European SmPC: it has no contraindication and only notes little experience with other QT-prolonging drugs (ranolazine FDA label). Start or restart dofetilide only in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and perform cardiac resuscitation, and keep the person there for at least three days (dofetilide FDA label). Calculate creatinine clearance before the first dose. Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) is above 440 ms, or above 500 ms with ventricular conduction abnormalities (dofetilide FDA label). Bring potassium into the normal range before starting dofetilide and keep it there throughout treatment (dofetilide FDA label). If QT or QTc exceeds 500 ms (550 ms with ventricular conduction abnormalities) at any time after the second dose, stop dofetilide (dofetilide FDA label). After stopping dofetilide to switch to a potentially interacting drug, wait at least two days before starting that drug (dofetilide FDA label). Use ranolazine with caution in congenital or familial long QT syndrome, known acquired QT prolongation and with other drugs that affect the QT interval (ranolazine SmPC, EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dofetilide

Other interactions with Ranolazine